Position of the Transparency Council – Alecensa (alectinib)
At its meeting on 7 January 2025, the Transparency Council adopted position No. 1/2025 on the evaluation of the drug Alecensa (alectinib) under the drug program B.6 “Treatment of patients with lung cancer (ICD-10 C34) and pleural mesothelioma (ICD-10 C45)”